Track Blinklab Limited — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Blinklab Limited BB1.AX · Stock Open Blinklab Limited in new tab

0.6200 AUD
EPS
-0.06
P/B
4.61
ROE
-50.72
Beta
1.45
Target Price
2.24 AUD
Loading chart...
Key Metrics
Earnings dateFeb. 23, 2027
EPS-0.06
Book Value0.13
Price to Book4.61
Debt/Equity1.99
% Insiders33.415%
Growth
Revenue Growth3.87%
Estimates
Forward P/E-12.04
Forward EPS-0.05
Target Mean Price2.24

DCF valuation

Model fair value for Blinklab Limited (BB1.AX)
Result
Sign in to run the valuation for BB1.AX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus None · mean target 2.24 AUD (low 1.76, high 3.06) · as of 19 Oct 2026
Low 1.76
Mean 2.24
High 3.06
Price 0.6200
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Blinklab Limited Logo Blinklab Limited Analysis (BB1.AX)

Australia Healthcare Official Website Stock

Is Blinklab Limited a good investment? Blinklab Limited (BB1.AX) is currently trading at 0.6200 AUD. Market analysts have a consensus price target of 2.24 AUD. This suggests a potential upside from current levels.

Earnings Schedule: Blinklab Limited is expected to release its next earnings report on Feb. 23, 2027. The market consensus estimate for Forward EPS is -0.05.

Investor FAQ

Does Blinklab Limited pay a dividend?

No, it does not currently pay a dividend.

What asset class is Blinklab Limited?

Blinklab Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 23, 2027. The company currently has a trailing EPS of -0.06.

Company Profile

BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-based neurobehavioural testing. Its smartphone-based application serves as a device for conducting neurobehavioral evaluations and objective sensorimotor biomarkers, which provides scientific support for future regulatory approval and clinical adoption. The company's application also enables remote and rapid testing to aid research on neurodevelopmental and neurodegenerative conditions such as schizophrenia, autism, attention deficit hyperactivity disorder (ADHD), and various forms of dementia. The company was incorporated in 2021 and is based in Perth, Australia.

Exchange Ticker
BB1.AX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion